Related Experiment Video
Updated: Aug 25, 2025
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Evidence-based support for phenotypic drug discovery in acute myeloid leukemia
Sean Vandersluis1, Jennifer C Reid1, Luca Orlando1
1Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
Abstract:
The discovery and development of effective drugs for cancer patients has seen limited success in the clinic from phase I trials onward. The high attrition rate of current drug development approaches requires careful evaluation to provide a better understanding of the factors that correlate with or predict positive clinical outcomes. Here, we examine pre-clinical drug development approaches and conduct a meta-analysis of 2918 clinical studies involving 466 unique drugs tested in clinical trials for acute myeloid leukemia (AML). Our goal was to determine whether there are key shared pre-clinical characteristics that ultimately relate to successful or unsuccessful drugs in patients. We provide an evidence-based recommendation for the use of phenotypic drug discovery rather than other methods during pre-clinical development. Although our analysis was limited to AML, similar analyses are likely to be informative for other tumor-specific drug discovery campaigns, informing and improving the foundational discovery screens and platforms for other cancers.
Insights
Phenotypic drug discovery shows promise for improving cancer drug development. This meta-analysis of acute myeloid leukemia (AML) trials suggests focusing on this approach to increase clinical success rates.
Area of Science:
- Oncology
- Pharmacology
- Translational Medicine
Background:
- Cancer drug development faces high attrition rates from early clinical trials.
- Understanding factors predicting clinical success is crucial for improving drug development pipelines.
- Acute myeloid leukemia (AML) serves as a model for investigating drug development challenges.
Approach:
- A comprehensive meta-analysis of 2918 clinical studies involving 466 unique drugs tested in AML.
- Examination of pre-clinical drug development strategies and their correlation with clinical outcomes.
- Comparative analysis of different pre-clinical drug discovery methods.
Key Points:
- Phenotypic drug discovery demonstrated a stronger correlation with positive clinical outcomes compared to other pre-clinical methods.
- Identified shared pre-clinical characteristics that distinguish successful from unsuccessful drugs in AML.
- The study highlights the need for evidence-based recommendations in pre-clinical drug selection.
Conclusions:
- Phenotypic drug discovery is recommended as a preferred pre-clinical approach for cancer therapeutics.
- Findings from AML drug development may inform and improve discovery platforms for other cancer types.
- Optimizing pre-clinical strategies can enhance the efficiency and success rate of clinical cancer drug development.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...